Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 5/20 | 0.59 |
| ▸ | PLAU | P00749 | 3/20 | 0.59 |
| ▸ | BACE1 | P56817 | 2/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 11/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30035233 | 1.00 | NCF1 (0.59) | NCF1PLAUBACE1MCHR1LMNA | |
| SCHEMBL845037 | 0.82 | SLC40A1 (0.45) | NCF1PLAUBACE1MCHR1LMNA | |
| SCHEMBL29683992 | 0.82 | SLC40A1 (0.45) | NCF1PLAUBACE1MCHR1LMNA | |
| SCHEMBL21975961 | 0.77 | NCF1 (0.63) | NCF1PLAUBACE1MCHR1NOS2 | |
| SCHEMBL6845198 | 0.75 | NCF1 (0.58) | NCF1PLAUBACE1MCHR1NOS2 | |
| SCHEMBL23548885 | 0.74 | XPO1 (0.41) | LMNAPDE10A | |
| SCHEMBL15228915 | 0.74 | BACE1 (1.00) | NCF1PLAUBACE1MCHR1NOS2 | |
| SCHEMBL2757274 | 0.74 | METAP2 (0.59) | — | |
| SCHEMBL361523 | 0.74 | NCF1 (1.00) | NCF1PLAUBACE1MCHR1 | |
| SCHEMBL3850693 | 0.74 | XPO1 (0.41) | BACE1LMNAPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2025-10-02 | — | — | US | disclosed |
| WO-2024152743-A1 | QUINOLINE DERIVATIVE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏柯菲平医药股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-117222639-A | Quinoline amine compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2022247920-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | 江苏恒瑞医药股份有限公司 | 2022-12-01 | — | — | WO | disclosed |
| EP-3088397-A1 | COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2152692-B1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO LTD (JP) | 2016-06-15 | — | — | EP | disclosed |
| WO-2009031040-A2 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | NCF1 1417/4885PLAU 575/4885BACE1 4877/4885 |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | NCF1 282/4885PLAU 4662/4885BACE1 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.